- Global Pharma News & Resources

Hormone Replacement Therapy Market Few Ways You Can Apply Your Creativity Using It.

The Hormone Replacement Therapy Market analysis report speaks about the growth rate till 2027 manufacturing process, Growth, key factors driving this market with sales, revenue, and price analysis of lead manufacturers, distributors, traders and dealers of Hormone Replacement Therapy.

Request Here Sample Report


One of the key factors fueling the growth of the global hormone replacement therapy market is increasing acquisitions. Pfizer Inc., a pharmaceutical firm headquartered in the United States, combined with OPKO Health Inc., a business based in the U.S., in 2014 to create a long-acting growth hormone (hGH-CTP) and novel therapies for growth hormone deficient individuals. hGH-CTP is more convenient since patients just require one injection each week instead of daily dosages. In the U.S. and Europe, hGH-CTP has been designated as an orphan medication for children and adults with growth hormone deficiencies.

The expansion of the global hormone replacement therapy market is projected to be aided by a strong pipeline. In 2017, Novo Nordisk A/S, a Danish firm, completed phase 3 clinical studies for Somapacitan. This medication is used to treat adult testosterone deficiency.

The prominent players in the Hormone Replacement Therapy Market are Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

Buy This Complete A Business Report With Flat US $2000 Off @


The market for hormone replacement treatment is projected to expand due to the rising prevalence of various chronic diseases.

The market for hormone replacement treatment is projected to expand due to the rising prevalence of hypogonadism in adult males throughout the world. Hypogonadism affects 2.1 percent to 12.8 percent of middle-aged men, according to the European Association of Urology’s 2016 study. In Europe, the prevalence of low testosterone and hypogonadism symptoms in males aged 40 to 79 ranges from 2.1 percent to 5.7 percent.

The expansion of the global hormone replacement therapy market is projected to be aided by easier access and government assistance for research and development efforts. NGOs such as the National Gaucher Society provide financial assistance to patients who require expensive insulin replacement treatment.


The global hormone replacement therapy market is anticipated to be hampered by stringent restrictions suggested by the U.S. Food and Drug Administration (FDA) governing the use of hormone replacement products, due to the rising risk of severe cardiovascular illnesses throughout the forecast period.

The U.S. Food and Drug Administration (FDA) amended regulations in February 2018, stating that testosterone replacement medication makers must modify labelling to alert patients about an elevated risk of heart attack and stroke.

Moreover, the FDA issued a regulation in January 2018 that would require testosterone suppliers to undertake a post-marketing randomized, double-blind, placebo-controlled experiment prior to actually promoting the product to verify whether this treatment tends to increase significant negative cardiovascular diseases such as myocardial infarction and stroke.

Regional Analysis

Due to the ongoing release of numerous generic hormone replacement therapy products by manufacturers, North America is projected to retain a prominent position in the global hormone replacement therapy market.

Moreover, Europe is anticipated to be the second biggest revenue contributor to the global hormone replacement therapy market, with considerable growth expected in the near future. This is due to the introduction of new medicines and therapies to treat secondary hyperparathyroidism, as well as the existence of a large population affected by the condition in this region. Etecalcetide (Parsabiv), an Amgen medication, was approved by the European Commission in December 2016 for the treatment of secondary hyperparathyroidism in elderly patients with chronic renal illness.

Due to rising healthcare-related concerns such as rising incidence of chronic illnesses, high prevalence of hypogonadism in men with type II diabetes mellitus, and rising diabetes prevalence in this area, Asia Pacific is anticipated to expand at the quickest rate throughout the forecast period. As per the International Diabetes Federation’s (IDF) Diabetes Atlas: 2017, the population of diabetics aged 20 to 79 years in the South East Asia and Western Pacific regions was 82 million and 159 million, accordingly, in 2017.

Competitive Landscape

Companies are concentrating their efforts on creating generic versions of numerous medications for the treatment of diseases that are more common in women, such as hypothyroidism. On July 24, 2017, Teva Pharmaceutical Industries Ltd. introduced a generic version of Vagifem, 10 mcg, in the United States. Estradiol vaginal inserts are a kind of oestrogen used to treat atrophic vaginitis caused by menopause.

Furthermore, Mylan N.V. received FDA clearance for its Abbreviated New Medication Application (ANDA) for Estradiol Vaginal Cream USP, 0.01 percent on December 29, 2017, and therefore marketed the drug in the U.S. This cream is the first generic alternative to Allergan’s Estrace Cream, which is used to treat vulvar and vaginal atrophy.

Mylan is one of the few firms that sells Estradiol in cream, gel, transdermal patch, and tablet form. This will benefit both healthcare personnel and patients, as well as ensuring the business’s long-term viability.

Major companies contributing in the global hormone replacement therapy market are Pfizer Inc., QuatRx Pharmaceuticals, Mylan N.V., Abbott Laboratories, Amgen, Inc., Novartis AG, Eli Lilly and Company, Bayer AG, Merck KgaA, Teva Pharmaceutical Industries Ltd., and Novo Nordisk A/S.

Request Here For PDF Brochure

Main points in Hormone Replacement Therapy Market Report Table of Content

Chapter 1 Industry Overview

1.1 Definition

1.2 Assumptions

1.3 Research Scope

1.4 Market Analysis by Regions

1.5 Global Hormone Replacement Therapy Market Size Analysis from 2021 to 2027

11.6 COVID-19 Outbreak: Hormone Replacement Therapy Industry Impact

Chapter 2 Global Hormone Replacement Therapy Competition by Types, Applications, and Top Regions and Countries

2.1 Global Hormone Replacement Therapy (Volume and Value) by Type

2.3 Global Hormone Replacement Therapy (Volume and Value) by Regions

Chapter 3 Production Market Analysis

3.1 Global Production Market Analysis

3.2 Regional Production Market Analysis

Chapter 4 Global Hormone Replacement Therapy Sales, Consumption, Export, Import by Regions (2016-2021)

Chapter 5 North America Hormone Replacement Therapy Market Analysis

Chapter 6 East Asia Hormone Replacement Therapy Market Analysis

Chapter 7 Europe Hormone Replacement Therapy Market Analysis

Chapter 8 South Asia Hormone Replacement Therapy Market Analysis

Chapter 9 Southeast Asia Hormone Replacement Therapy Market Analysis

Chapter 10 Middle East Hormone Replacement Therapy Market Analysis

Chapter 11 Africa Hormone Replacement Therapy Market Analysis

Chapter 12 Oceania Hormone Replacement Therapy Market Analysis

Chapter 13 South America Hormone Replacement Therapy Market Analysis

Chapter 14 Company Profiles and Key Figures in Hormone Replacement Therapy Business

Chapter 15 Global Hormone Replacement Therapy Market Forecast (2021-2027)

Chapter 16 Conclusions

View Press Release For More Information

Related Reports:

Reproductive Hormone Market, by Hormone Type (Testosterone, Estrogen, and Progesterone), by Application (Menopausal and Menstrual Disorders, Premenstrual Syndrome (PMS), Hypogonadism, and Others), by End User (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Testosterone Replacement Therapy Market, by Route of Administration (Injectables, Parenteral), by Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate) and by Geography -Size, Share, Outlook, and Opportunity Analysis 2019 –2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 18-Aug-2021